Is MRVT or MRK a better dividend investment in 2026?

MRVT currently yields 66666.67% with a 5% 5-year dividend growth rate. MRK yields 2.76% with 8.2% growth. The better choice depends on your goal: MRVT offers higher current income.

What is the dividend yield difference between MRVT and MRK?

MRVT has a forward dividend yield of 66666.67% ($2.00/share annually). MRK yields 2.76% ($3.32/share annually). The yield gap is 66663.91 percentage points.

Home › Compare › MRVT vs MRK

MRVT vs MRK: Dividend Comparison 2026

MRVT yields 66666.67% · MRK yields 2.76%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 MRVT wins by $8.441837856534449e+24M in total portfolio value

INVESTMENT

TIME HORIZON10 years

MRVT

● Live price

66666.67%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$8.441837856534449e+24M

Annual income

$8,417,001,582,403,749,000,000,000,000,000.00

Full MRVT calculator →

MRK

Merck & Co. Inc.

● Live price

2.76%

Share price

$120.31

Annual div

$3.32

5Y div CAGR

32.7%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$56.8K

Annual income

$9,798.13

Full MRK calculator →

Portfolio growth — MRVT vs MRK

📍 MRVT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	MRVT	MRK
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, MRVT + MRK cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

MRVT pays

MRK pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MRVT

Annual income on $10K today (after 15% tax)

$5,666,666.67/yr

After 10yr DRIP, annual income (after tax)

$7,154,451,345,043,187,000,000,000,000,000.00/yr

MRK

Annual income on $10K today (after 15% tax)

$234.56/yr

After 10yr DRIP, annual income (after tax)

$8,328.41/yr

At 15% tax rate, MRVT beats the other by $7,154,451,345,043,187,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MRVT + MRK for your $10,000?

MRVT: 50%MRK: 50%

100% MRK50/50100% MRVT

Portfolio after 10yr

$4.2209189282672247e+24M

Annual income

$4,208,500,791,201,874,400,000,000,000,000.00/yr

Blended yield

99.71%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

MRVT

No analyst data

Altman Z

-63.1

Piotroski

2/9

MRK

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$128.54

+6.8% upside vs current

Range: $100.00 — $150.00

Altman Z

4.0

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MRVT buys

MRK buys

No recent congressional trades found for MRVT or MRK in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricMRVTMRK

Forward yield	66666.67% ✓	2.76%
Annual dividend / share	$2.00	$3.32 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	32.7% ✓
Portfolio after 10y	$8.441837856534449e+24M	$56.8K ✓
Annual income after 10y	$8,417,001,582,403,749,000,000,000,000,000.00 ✓	$9,798.13
Total dividends collected	$8.44020886744369e+24M	$28.9K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: MRVT vs MRK ($10,000, DRIP)

Year	MRVT Portfolio	MRVT Income/yr	MRK Portfolio	MRK Income/yr	Gap
1← crossover	$6,677,367	$6,666,666.67	$11,206	$366.19	+$6.67M → MRVT
2	$4,167,497,846	$4,160,353,063.34	$12,650	$502.35	+$4167.49M → MRVT
3	$2,431,161,901,635	$2,426,702,678,939.67	$14,407	$694.19	+$2431161.89M → MRVT
4	$1,325,636,209,022,888	$1,323,034,865,788,139.00	$16,585	$967.82	+$1325636209.01M → MRVT
5	$675,632,775,263,916,700	$674,214,344,520,262,300.00	$19,342	$1,363.89	+$675632775263.90M → MRVT
6	$321,867,481,182,444,260,000	$321,144,554,112,911,900,000.00	$22,913	$1,947.19	+$321867481182444.25M → MRVT
7	$143,326,993,661,751,470,000,000	$142,982,595,456,886,240,000,000.00	$27,662	$2,823.89	+$143326993661751472.00M → MRVT
8	$59,657,925,421,851,500,000,000,000	$59,504,565,538,633,426,000,000,000.00	$34,159	$4,173.35	+$59657925421851500544.00M → MRVT
9	$23,211,471,150,187,795,000,000,000,000	$23,147,637,169,986,416,000,000,000,000.00	$43,337	$6,308.80	+$2.3211471150187796e+22M → MRVT
10	$8,441,837,856,534,450,000,000,000,000,000	$8,417,001,582,403,749,000,000,000,000,000.00	$56,776	$9,798.13	+$8.441837856534449e+24M → MRVT

MRVT vs MRK: Complete Analysis 2026

MRVT — Stock

Miravant Medical Technologies Inc. operates as a pharmaceutical research and development company. The company develops PhotoPoint, a photodynamic therapy that responds to light destroying cancerous cells; and manufactures light producing and light delivery devices. Its products include PHOTREX for the treatment of wet age-related macular degeneration or AMD; MV9411, a photoreactive drug for the treatment of plaque psoriasis; MV0633 for the treatment of atherosclerosis, atherosclerotic vulnerable plaque, and restenosis; MV2101 for the treatment of vascular access graft disease in hemodialysis patients; and MV6401 for the treatment of solid tumors. Miravant Medical Technologies Inc. was formerly known as PDT, Inc. and changed its name to Miravant Medical Technologies Inc. in September 1997. The company was founded in 1989 and is headquartered in Santa Barbara, California.

Full MRVT Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →

📬

Get this MRVT vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MRVT vs SCHD MRVT vs JEPI MRVT vs O MRVT vs KO MRVT vs MAIN MRVT vs JNJ MRVT vs ABBV MRVT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.